Human Liver-Derived Stem Cells Improve Fibrosis and Inflammation Associated with Nonalcoholic Steatohepatitis.
Stefania BrunoMaria Beatriz Herrera SanchezChiara PasquinoMarta TapparoMassimo CedrinoCiro TettaGiovanni CamussiPublished in: Stem cells international (2019)
Cell therapy may be regarded as a feasible alternative to whole organ transplantation to treat end-stage liver diseases. Human liver stem cells (HLSCs) are a population of cells easily obtainable and expandable from a human adult liver biopsy. HLSCs share with mesenchymal stromal cells the same phenotype, gene expression profile, and differentiation capabilities. In addition, HLSCs show a specific commitment to the hepatic phenotype. Injection of HLSCs into immunodeficient mice fed with a methionine-choline-deficient diet to induce nonalcoholic steatohepatitis ameliorates liver function and morphology. In particular, HLSC treatment induced a reduction of liver fibrosis and inflammation at morphological and molecular levels. Moreover, HLSCs were able to persist for up to 3 weeks after the injection. In conclusion, HLSCs have healing effects in a model of chronic liver disease.
Keyphrases
- cell therapy
- stem cells
- liver fibrosis
- oxidative stress
- ultrasound guided
- endothelial cells
- induced apoptosis
- mesenchymal stem cells
- high glucose
- diabetic rats
- type diabetes
- weight loss
- genome wide
- cell cycle arrest
- dna methylation
- gene expression
- drug induced
- signaling pathway
- induced pluripotent stem cells
- high fat diet induced
- replacement therapy
- young adults
- fine needle aspiration
- stress induced